Status:
COMPLETED
A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Prostate Cancer
Head & Neck Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess the feasibility of combined administration of different LBH589 dosages with radiotherapy in order to establish the dosage to be evaluated in future studies.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients with age ≥18 years
- Confirmed diagnosis of prostate cancer, SCC esophageal cancer or head \& neck cancer
- No evidence of distant spread of the disease
- Exclusion criteria:
- Patients who have severe and/or uncontrolled medical conditions
- Female patients who are pregnant or breast feeding
- Other protocol-defined inclusion/exclusion criteria may apply
Exclusion
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT00670553
Start Date
September 1 2008
End Date
January 1 2010
Last Update
May 17 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Liège, Belgium